Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement

2026-03-02 14:35:28 ET

The last time I spoke about Compugen ( CGEN ), it was with respect to a Seeking Alpha article entitled " Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients ." With respect to this article, I went over the fact that the company was in the process of evaluating the use of its anti-PVRIG antibody COM701 as a maintenance treatment for patients with platinum-sensitive ovarian cancer ((PSOC)) in the ongoing phase 3 MAIA-Ovarian cancer trial. The latest update for the advancement of this clinical program is that an interim analysis from this late-stage study is on track to be released in Q1 of 2027. The last time around I had a "Buy" rating on this stock, and I believe that it is important to maintain this rating....

Read the full article on Seeking Alpha

For further details see: